Streamed video of CEO Martin Vidaeus presenting at Aktieportföljen Live in Stockholm, Sweden on Oct. 11, 2022

Get an update of the development activities surrounding Redwood Pharma’s two products for the treatment of dry eye disease, its near-term plans for seeking RP501 regulatory approval, scaling up of production, commercialization and launch. More information about the coming rights issue in November is also provided by CEO Martin Vidaeus.

To view the presentation and a question and answer session, please see the following link:

https://youtu.be/oO_Ytq3idwQ